<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iron sucrose: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iron sucrose: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iron sucrose: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9004" href="/d/html/9004.html" rel="external">see "Iron sucrose: Drug information"</a> and <a class="drug drug_patient" data-topicid="11974" href="/d/html/11974.html" rel="external">see "Iron sucrose: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F184604"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Venofer</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867263"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-Iron Sucrose;</li>
<li>Venofer</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1020337"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Iron Salt, Parenteral</span>;</li>
<li>
<span class="list-set-name">Mineral, Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462479"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: Multiple forms of parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or underdosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses are expressed as mg of <b>elemental iron</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7550fb40-3093-4c4a-b6f9-a129f7bec73b">Anemia of prematurity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia of prematurity:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm Neonates: <b>Note:</b> In clinical studies, parenteral iron was used (as an alternative to enteral iron) in combination with erythropoietin.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daily regimen: </i>1 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11134438','lexi-content-ref-Pollak.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11134438','lexi-content-ref-Pollak.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Biweekly regimen: </i>1.5 mg/kg/dose twice weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31940698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31940698'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weekly regimen:</i> 3 to 6 mg/kg/dose once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8765624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8765624'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F6010345"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: Multiple forms of parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or underdosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses are expressed as mg of <b>elemental iron</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1419c044-7d76-4ba1-b263-ea0f5decd036">Iron-deficiency anemia in chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia in chronic kidney disease (CKD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Repletion treatment:</i> Limited data available: Children ≥2 years and Adolescents ≤15 years: IV: 1 mg/kg/dose per dialysis session; repeat dose with each dialysis session until patient-specific lab goals are met, then follow with maintenance dosing. Dosing based on a dose-finding trial in 14 pediatric patients (ages 2 to 15 years) receiving iron sucrose in combination with epoetin for absolute or functional iron deficiency. Due to a rapid increase in ferritin levels (from 59 mcg/L to 496 mcg/L) observed in the first 6 weeks of the trial, the dosing protocol for iron sucrose was changed from 3 mg/kg/dose per dialysis session to 1 mg/kg/dose per dialysis session; the dose of 1 mg/kg/dose per dialysis session was continued until a patient was considered replete based on study criteria, at which point the patient was transitioned to the maintenance group within the study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15365964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15365964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance therapy:</i> Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis-dependent CKD: IV: 0.5 mg/kg/dose every 2 weeks for 12 weeks (6 doses); maximum dose: 100 mg/dose; may repeat if clinically indicated.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis-dependent CKD (in combination with erythropoietin therapy): IV: 0.5 mg/kg/dose every 4 weeks for 12 weeks (3 doses); maximum dose: 100 mg/dose; may repeat if clinically indicated.</p>
<p style="text-indent:-2em;margin-left:6em;">Nondialysis-dependent CKD (in combination with erythropoietin therapy): IV: 0.5 mg/kg/dose every 4 weeks for 12 weeks (3 doses); maximum dose: 100 mg/dose; may repeat if clinically indicated.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c8f1cb9-6428-4129-a11b-2e46c05cac10">Iron-deficiency anemia, treatment, patients without chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment, patients without chronic kidney disease: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 2.5 to 7 mg/kg/dose; repeat every 3 to 7 days until patient-specific goals are met or total calculated deficit replaced; maximum dose: 300 mg/dose; less frequent administration has been reported and some experts recommend maximum initial dose of 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21298748','lexi-content-ref-27199624','lexi-content-ref-27540710','lexi-content-ref-32947565','lexi-content-ref-28562517','lexi-content-ref-21586412','lexi-content-ref-18605353','lexi-content-ref-28704225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21298748','lexi-content-ref-27199624','lexi-content-ref-27540710','lexi-content-ref-32947565','lexi-content-ref-28562517','lexi-content-ref-21586412','lexi-content-ref-18605353','lexi-content-ref-28704225'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51128326"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Nondialyzable. There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51128327"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F184607"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9004" href="/d/html/9004.html" rel="external">see "Iron sucrose: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose is expressed in mg of elemental iron. A test dose typically is not required<b>.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations</b>
<b>: </b>IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, need for rapid repletion, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea1faddf-83d5-47dd-8983-0f9025bbcc3c">Chemotherapy-associated anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-associated anemia (off-label use): IV:</b> 200 mg once every 3 weeks for 5 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18375890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18375890'])">Ref</a></span>) <b>or</b> 100 mg once weekly during weeks 0 to 6, followed by 100 mg every other week from weeks 8 to 14 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17252006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17252006'])">Ref</a></span>) <b>or </b>200 mg once a week after each platinum-based chemotherapy cycle for up to 6 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17234260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17234260'])">Ref</a></span>) <b>or </b>200 mg after each platinum-based chemotherapy cycle for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24099839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24099839'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1419c044-7d76-4ba1-b263-ea0f5decd036">Iron-deficiency anemia in chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia in chronic kidney disease:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hemodialysis-dependent chronic kidney disease:</i> 100 mg administered during consecutive dialysis sessions; the usual cumulative total dose is 1,000 mg (10 doses); may repeat treatment if clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peritoneal dialysis-dependent chronic kidney disease:</i> Two infusions of 300 mg administered 14 days apart, followed by a single 400 mg infusion 14 days later (total cumulative dose of 1,000 mg in 3 divided doses); may repeat treatment if clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-dialysis-dependent chronic kidney disease:</i> 200 mg administered on 5 different occasions within a 14-day period (total cumulative dose: 1,000 mg in 14-day period); may repeat treatment if clinically indicated. <b>Note:</b> Dosage has also been administered as 2 infusions of 500 mg on day 1 and day 14 (limited experience).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c8f1cb9-6428-4129-a11b-2e46c05cac10">Iron-deficiency anemia, treatment, patients without chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment, patients without chronic kidney disease (off-label use): IV:</b> 100 to 300 mg per dose; repeat doses may be given until total iron requirements are met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31243803','lexi-content-ref-28189173','lexi-content-ref-32297281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31243803','lexi-content-ref-28189173','lexi-content-ref-32297281'])">Ref</a></span>). Dosing schedule depends on iron deficit and ease of scheduling. Cumulative doses &gt;1 g generally are not required during a single treatment course unless there is ongoing blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991420"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); limited amounts of iron (~5%) eliminated in urine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14718064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14718064'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large molecular weight): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988669"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58646165"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rates of infusion reactions associated with IV iron preparations vary across studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35353168','lexi-content-ref-26575062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35353168','lexi-content-ref-26575062'])">Ref</a></span>); higher rates of infusion reactions with iron sucrose compared to other formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35353168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35353168'])">Ref</a></span>). Immediate <b>hypersensitivity reactions</b> to IV iron preparations, including iron sucrose, range in severity from mild self-limited reactions (eg, <b>pruritus</b>, urticaria, asymptomatic <b>hypotension</b>) to severe <b>anaphylaxis</b> and <b>anaphylactic shock</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26759045','lexi-content-ref-25420283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26759045','lexi-content-ref-25420283'])">Ref</a></span>). Transient flushing and truncal myalgias, known as Fishbane reactions, occur in ~30% of all infusion reactions, quickly resolve after discontinuing the infusion, and do not recur when the infusion is restarted at a slower rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36291409','lexi-content-ref-33248279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36291409','lexi-content-ref-33248279'])">Ref</a></span>). Delayed hypersensitivity reactions, most often exanthematous cutaneous reactions, have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33248279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33248279'])">Ref</a></span>). There is a lack of cross-reactivity between iron sucrose and iron dextran (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21304025','lexi-content-ref-10873877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21304025','lexi-content-ref-10873877'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; may be immunologic or nonimmunologic (more common) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26265306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26265306'])">Ref</a></span>). Immediate hypersensitivity reactions (eg, anaphylaxis): mechanism unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36291409','lexi-content-ref-25420283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36291409','lexi-content-ref-25420283'])">Ref</a></span>). Nonimmunologic reactions (eg, Fishbane reactions) may be due to activation of complement, referred to as complement activation-related pseudo-allergy (CARPA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30937914','lexi-content-ref-25420283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30937914','lexi-content-ref-25420283'])">Ref</a></span>). Delayed hypersensitivity reactions are commonly T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36291409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36291409'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occur most frequently within the first 10 minutes of the infusion but may occur more than 30 minutes after completion of the infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30937914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30937914'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose and faster infusion rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30937914','lexi-content-ref-25420283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30937914','lexi-content-ref-25420283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous reaction to IV iron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25420283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25420283'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">IV iron, including iron sucrose, may be associated with an increased risk of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23950195','lexi-content-ref-29103332','lexi-content-ref-34767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23950195','lexi-content-ref-29103332','lexi-content-ref-34767026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; IV iron can increase levels of non–transferrin-bound iron, which can lead to impaired T-cell and neutrophil function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34767026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; can occur after single- or multiple-dose administrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34767026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with inflammatory bowel disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34767026'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Iron overload</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Excessive iron therapy may lead to iron overload (with the possibility of iatrogenic hemosiderosis) in patients with kidney failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22435497','lexi-content-ref-26342303','lexi-content-ref-27091216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22435497','lexi-content-ref-26342303','lexi-content-ref-27091216'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; occurs when administered iron exceeds the carrying capacity of transferrin, leading to the release of labile, non–transferrin-bound iron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31477259','lexi-content-ref-27091216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31477259','lexi-content-ref-27091216'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; following chronic exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26759045','lexi-content-ref-31338466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26759045','lexi-content-ref-31338466'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> High IV iron doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29153377','lexi-content-ref-29956370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29153377','lexi-content-ref-29956370'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F184579"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults with hemodialysis dependent (HDD), non-dialysis dependent (NDD), and/or peritoneal dialysis dependent (PDD) chronic kidney disease (CKD), unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (children and adolescents: 2%; adults: HDD-CKD: 39%, NDD/PDD-CKD: 2% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension" frame="border" id="lexi-content-hypotension" rules="all">
<caption style="text-align:center;">
<b>Iron Sucrose: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Iron Sucrose)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Iron Sucrose)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">HDD-CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">231</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">NDD-CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Oral iron</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">PDD-CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">75</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Erythropoietin</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (children and adolescents: 3%; adults: 5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (children and adolescents: 6%; adults: HDD-CKD: 13%, NDD/PDD-CKD: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (HDD-CKD: 29%, NDD/PDD-CKD: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (≤16%) pharyngitis (≤16%), sinusitis (≤16%), upper respiratory tract infection (≤16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arteriovenous fistula site complication (thrombosis: children: 2%), chest pain (1% to 6%), heart failure (&gt;1%), hypertension (children and adolescents: 2%; adults: 7% to 8%), peripheral edema (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pruritus')">table 2</a>)</span><span class="table-link" style="display:none;">Pruritus</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pruritus" frame="border" id="lexi-content-pruritus" rules="all">
<caption style="text-align:center;">
<b>Iron Sucrose: Adverse Reaction: Pruritus</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Iron Sucrose)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Iron Sucrose)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">HDD-CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">231</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">NDD-CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Oral iron</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">PDD-CKD</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">75</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">46</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Erythropoietin</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (3%), hypervolemia (1% to 3%), hypoglycemia (HDD/NDD-CKD: &lt;1%, PDD-CKD: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 4%), diarrhea (5% to 8%), dysgeusia (≤8%), peritonitis (children: 4%), vomiting (children and adolescents: 4%; adults: 5% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction (≤6%; including burning and infusion-site pain)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤3%), dizziness (children and adolescents: 4%; adults: HDD/NDD-CKD: 7%, PDD-CKD: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 4%), back pain (1% to 2%), gout (3%), limb pain (3% to 6%), myalgia (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children and adolescents: 4%; adults: 1% to 3%), dyspnea (1% to 6%), nasal congestion (1%), viral respiratory tract infection (children: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: 4%; adults: ≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, collapse, ischemic heart disease, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylactic shock, anaphylaxis, and angioedema) (Behera 2015, Mishra 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, loss of consciousness, paresthesia, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p></div>
<div class="block coi drugH1Div" id="F184593"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to iron sucrose or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labeling): Iron overload; anemia not caused by iron deficiency</p></div>
<div class="block war drugH1Div" id="F184577"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Clinically significant hypotension has been reported; monitor for signs/symptoms of hypotension. Hypotension may be related to total dose or rate of administration (avoid rapid IV injection).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878504"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use parenteral iron products with caution in premature neonates; necrotizing enterocolitis has been reported; however, no causal relationship established. </p></div>
<div class="block dosfc drugH1Div" id="F21963477"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strength of iron sucrose is expressed as elemental iron.</p></div>
<div class="block foc drugH1Div" id="F184587"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venofer: 20 mg/mL (2.5 mL, 5 mL, 10 mL)</p></div>
<div class="block geq drugH1Div" id="F184573"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323230"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Venofer Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $8.83</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867264"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venofer: 20 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (5 mL)</p></div>
<div class="block adip drugH1Div" id="F53567253"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Contains sucrose: 300 mg/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficit (total replacement dose needed [mg of iron]) = 0.6 × weight (kg) × [100 − (actual hemoglobin/target hemoglobin × 100)] (Goyal 2020; Norman 2011).</p></div>
<div class="block admp drugH1Div" id="F52613086"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: May administer IV; not for IM use.</p>
<p style="text-indent:-2em;margin-left:2em;">Premature Neonates: Infusion: Infuse over at least 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8765624','lexi-content-ref-11134438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8765624','lexi-content-ref-11134438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of iron deficiency anemia in patients with chronic kidney disease (CKD):</p>
<p style="text-indent:-2em;margin-left:6em;">Slow IV injection: Administer undiluted over 5 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Infusion: Dilute and infuse over 5 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Iron deficiency anemia in patients without CKD: Infuse diluted doses over 30 to 90 minutes (reported range: 15 minutes to 3.5 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21298748','lexi-content-ref-27199624','lexi-content-ref-28562517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21298748','lexi-content-ref-27199624','lexi-content-ref-28562517'])">Ref</a></span>). Some experts recommend to dilute to 1 mg/mL and infuse at 1 to 1.3 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32947565','lexi-content-ref-18605353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32947565','lexi-content-ref-18605353'])">Ref</a></span>). Undiluted doses (≤200 mg) may be infused as slow IV push (eg, over 5 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32947565','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32947565','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Others recommend the following infusion times based on dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21298748','lexi-content-ref-21586412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21298748','lexi-content-ref-21586412'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">For doses ≤100 mg, infuse over at least 30 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">For doses &gt;100 mg and ≤200 mg, infuse over at least 60 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">For doses &gt;200 mg and ≤300 mg, infuse over at least 90 minutes.</p></div>
<div class="block adm drugH1Div" id="F184590"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer intravenously as a slow IV injection (<b>not</b> for rapid IV injection) or as an IV infusion. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available. Can be administered through dialysis line.</p>
<p style="text-indent:-2em;margin-left:4em;">Slow IV injection: May administer doses ≤200 mg undiluted by slow IV injection over 2 to 5 minutes. When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session (generally within the first hour).</p>
<p style="text-indent:-2em;margin-left:4em;">Infusion: Infuse diluted doses ≤200 mg over at least 15 minutes; infuse diluted 300 mg dose over 1.5 hours; infuse diluted 400 mg dose over 2.5 hours; infuse diluted 500 mg dose over 3.5 to 4 hours (limited experience). When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session.</p></div>
<div class="block sts drugH1Div" id="F184600"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials in original carton at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze. Iron sucrose is stable for 7 days at room temperature (23°C to 27°C [73°F to 81°F]) or under refrigeration (2°C to 6°C [36°F to 43°F]) when undiluted in a plastic syringe or following dilution in normal saline in a plastic syringe (concentration 2 to 10 mg/mL) or for 7 days at room temperature (23°C to 27°C [73°F to 81°F]) following dilution in normal saline in an IV bag (concentration 1 to 2 mg/mL).</p></div>
<div class="block usep drugH1Div" id="F53567401"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of iron deficiency anemia in hemodialysis-dependent chronic kidney disease (CKD) (FDA approved in ages ≥2 years and adults); treatment of iron deficiency anemia with concurrent erythropoietin therapy in peritoneal dialysis-dependent CKD and nondialysis-dependent CKD (FDA approved in ages ≥2 years); treatment of iron deficiency anemia in peritoneal dialysis-dependent CKD and nondialysis-dependent CKD (FDA approved in adults); has also been used for treatment of anemia of prematurity and iron deficiency anemia in patients without chronic kidney disease.</p></div>
<div class="block mst drugH1Div" id="F7897706"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Iron sucrose may be confused with ferric carboxymaltose, ferric gluconate, ferumoxytol, iron dextran complex</p>
<p style="text-indent:-2em;margin-left:4em;">Venofer may be confused with Vfend, Vimpat</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299545"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F184581"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F184594"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;">There is a risk of adverse maternal reactions (eg, anaphylaxis, hypotension, shock) following use of parenteral iron that may result in fetal bradycardia, especially during the second and third trimesters. Although the risk is rare, immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021), Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Parenteral iron therapy may be used in pregnant patients who cannot tolerate or respond to oral iron, when iron deficiency occurs later in pregnancy, or when malabsorption is present (ACOG 2021; BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Iron sucrose has been evaluated in multiple studies for the treatment of IDA during pregnancy (Govindappagari 2019; Hamm 2021; Lewkowitz 2019; Qassim 2018; Qassim 2019; Radhika 2019; Rogozińska 2021; Shin 2021). However, due to limited safety data in early pregnancy, use of IV iron is generally not started until the second or third trimester (ACOG 2021; BSH [Pavord 2020]; FIGO 2019).</p></div>
<div class="block mopp drugH1Div" id="F53567376"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs/symptoms of hypersensitivity reactions (during and ≥30 minutes following infusion); hypotension (during and following infusion). In patients at risk of iron overload, monitor hemoglobin, hematocrit, serum ferritin, and transferrin saturation. If assessing iron status, measurements should be performed ≥48 hours after last dose (due to rapid increase in values following administration).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Chronic kidney disease</i>: Hematocrit, hemoglobin, serum ferritin, serum iron, transferrin, percent transferrin saturation (TSAT), total iron-binding capacity.</p>
<p style="text-indent:-2em;margin-left:4em;">Evaluate iron status (TSAT and ferritin) when deciding to start or continue iron therapy, and at least every 3 months in patients also receiving erythropoiesis-stimulating agent (ESA) therapy. Monitor ferritin and TSAT more frequently when monitoring response to IV iron therapy, when initiating or increasing ESA dose, when there is blood loss, and in any other situations where iron stores may become depleted (KDIGO 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Inflammatory bowel disease</i>: Monitor CBC, ferritin, TSAT, and C-reactive protein every 3 months for 1 year, then every 6 months for the following 5 years (if disease inactive) (Goyal 2020).</p></div>
<div class="block rerp drugH1Div" id="F53567247"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Serum iron (AAP [Kleinman 2019]):</p>
<p style="text-indent:-2em;margin-left:4em;">≤6 weeks: 100 to 250 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">7 weeks to 11 months: 40 to 100 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 10 years: 50 to 120 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">≥11 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 30 to 160 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 50 to 170 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">Total iron-binding capacity (AAP [Kleinman 2019]):</p>
<p style="text-indent:-2em;margin-left:4em;">≤2 months: 59 to 175 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">3 months to 17 years: 250 to 400 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">≥18 years: 240 to 450 mcg/dL.</p></div>
<div class="block pha drugH1Div" id="F184576"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose. The released iron increases serum iron concentrations and is incorporated into hemoglobin.</p></div>
<div class="block phk drugH1Div" id="F184592"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days</p>
<p style="text-indent:-2em;margin-left:2em;">Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Healthy adults: 7.9 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Dissociated into iron and sucrose by the reticuloendothelial system</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Healthy adults: 6 hours; Non-dialysis-dependent adolescents: 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Healthy adults: Urine (5%) within 24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F184595"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fermed | Ferosac</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dixafer | Energavit | Ferive | Ferrologic | Venofer</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anefer | Ferimax | Feristar | Feroven | Hemofer | Hemomax | Inofar | Kidifer | Unifer | Veniron</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ferropurum | Sucrofer</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Encifer | Hierro sacarosa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ferropurum | Glirron | Hierro sacarato | Hierro sacarosa | Hierronova</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fermed | Ferrologic | Venofer</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Encifer | Ferruvenol | Hierro sacarosa | Lucovit | Venofer</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dixafer | Encifer | Ferrocid | Ferrum hausmann | Glirron | Hierro sacarato | Hierro sacarosa | Venofer</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ferosac | Sacrofer</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Feriv | Hierro sacarosa normon | Venofer</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Iron sucrose injection usp | Sucrofer</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fer Actavis | Fer Mylan | Fer Panpharma | Fer Sandoz | Fer teva pharma | Venofer</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anemifer | Faremio | Ferrinemia | Ferrum hausman | Hemafer S | Ironcrose | Reoxyl | Veniron | Venofer</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ferrum hausmann</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dialifer | Foremic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Encifer | Fermia s | Feroject | Feronia | Globac safe | Haemaze forte | Hembeec is | Huntred | Jalika | Leferon | Livogen | Nufer | Raricap s | Richar XT | Roselina | Sucrofer | Sufecient | Uniferon | Uniraut | Venofer | Venoject | Vipron s | Vitcofol s</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ferroven | Ferrum hausmann</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ferrasil | Xeratec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Feppsol | Fesin mitsubishi | Fesin nichiiko</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ferosoft s | Ferracin | Ferrasil | Hemofer | Sucrofer | Venofer | Xeratec</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anemia | Anerrum | Femorrum | Ferrovin | Ferrowell | Hematin | Newferrum | Venoferrum | Venostin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ferosac</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ferrasil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ferrologic | Hemafer S | Venofer</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Glirron | Venoferrum</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ainiron | Avofer | Heamofer | Ranofer | Referis | Sucrofer | Venofer</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ferracin | Verient</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ferracin | Venofer</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ferrologic</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ciroferr | Encifer | Ferralip | Ferroviton s | Hierronim | Likferr | Prontofort | Sucrofer | Venofer | Zemcifer</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biorose | Encifer | Feromin | Ferriscript</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bisleri S | Cara fer | Fermax | Feroject | Ferosoft s | Ferplex SS | Ferris | Ferromit | Fersox | Fiore | Hadid | I Tose S | Ipase | Irose | Ivefer | Onefer | Rubiject | Sucrofer | Unifer | Venofer</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ferrinemia | Venofer</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Demrose | Emfer | Fermed | Feromax | Ferosac | Ferrasil | Sucrafer | Sukrofer | Tore | Venofer | Xeratec</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Argeferr | Fermed | Ferrum (iii) hydroxide saccharate | Irondext | Likferr | Venofer | Vialfer</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Blogen | Encifer</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Jaernsackaros Rechon | Venofer</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anerrum | Sucrofer | Venofer</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Feroven | Venofer</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Demrose | Ferint | Ferrosel | Ferroven | Inferose | Karferon | Sukrofer | Veniro | Venofer</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ferrum hausmann | Fesin | Good fe | Sucrofer</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Sufer</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ferracin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Hierro sacarato | Sucrox iv complex | Venofer</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ferroglass | Glirron | Hierro sacarosa</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Necrovi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Venofer</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28326596">
<a name="28326596"></a>Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.<i> Aliment Pharmacol Ther</i>. 2017;45(10):1303-1318. doi:10.1111/apt.14043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28326596/pubmed" id="28326596" target="_blank">28326596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8902444">
<a name="8902444"></a>al-Momen AK, al-Meshari A, al-Nuaim L, et al "Intravenous Iron Sucrose Complex in the Treatment of Iron Deficiency Anemia During Pregnancy," <i>Eur J Obstet Gynecol Reprod Biol</i>, 1996, 69(2):121-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/8902444/pubmed" id="8902444" target="_blank">8902444</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. <i>Pediatric Nutrition Handbook</i>. 8th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Anemia in pregnancy: ACOG practice bulletin, number 233. <i>Obstet Gynecol</i>. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35353168">
<a name="35353168"></a>Arastu AH, Elstrott BK, Martens KL, et al. Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions. <i>JAMA Netw Open</i>. 2022;5(3):e224488. doi:10.1001/jamanetworkopen.2022.4488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/35353168/pubmed" id="35353168" target="_blank">35353168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15327417">
<a name="15327417"></a>Aronoff GR, Bennett WM, Blumenthal S, et al, "Iron Sucrose in Hemodialysis Patients: Safety of Replacement and Maintenance Regimens," <i>Kidney Int</i>, 2004, 66(3):1193-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/15327417/pubmed" id="15327417" target="_blank">15327417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24099839">
<a name="24099839"></a>Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy.<i> Gynecol Oncol.</i> 2013;131(3):679-682. doi: 10.1016/j.ygyno.2013.09.028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/24099839/pubmed" id="24099839" target="_blank">24099839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auerbach.1">
<a name="Auerbach.1"></a>Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31243803">
<a name="31243803"></a>Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. <i>Am J Hematol.</i> 2019;94(9):1007-1014. doi:10.1002/ajh.25564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31243803/pubmed" id="31243803" target="_blank">31243803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22348897">
<a name="22348897"></a>Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. <i>Eur J Heart Fail</i>. 2012;14(4):423-429. doi:10.1093/eurjhf/hfs017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/22348897/pubmed" id="22348897" target="_blank">22348897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18375890">
<a name="18375890"></a>Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. <i>J Clin Oncol</i>. 2008;26(10):1611-1618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/18375890/pubmed" id="18375890" target="_blank">18375890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26085728">
<a name="26085728"></a>Behera V, Chauhan R, Sinha S, Nair V. Anaphylactic shock secondary to intravenous iron sucrose in chronic kidney disease. <i>Indian J Hematol Blood Transfus</i>. 2015;31(3):391-393. doi:10.1007/s12288-014-0475-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26085728/pubmed" id="26085728" target="_blank">26085728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28482869">
<a name="28482869"></a>Bhavi SB, Jaju PB. Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):137. doi: 10.1186/s12884-017-1313-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28482869/pubmed" id="28482869" target="_blank">28482869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30969847">
<a name="30969847"></a>Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>J Clin Oncol</i>. 2019;37(15):1336-1351. doi:10.1200/JCO.18.02142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30969847/pubmed" id="30969847" target="_blank">30969847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17302514">
<a name="17302514"></a>Breymann C, von Seefried B, Stahel M, Geisser P, Canclini C. Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex. <i>J Perinat Med</i>. 2007;35(2):115-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/17302514/pubmed" id="17302514" target="_blank">17302514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36291409">
<a name="36291409"></a>Caimmi S, Crisafulli G, Franceschini F, et al. Hypersensitivity to intravenous iron preparations. <i>Children (Basel)</i>. 2022;9(10):1473. doi:10.3390/children9101473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/36291409/pubmed" id="36291409" target="_blank">36291409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11684551">
<a name="11684551"></a>Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. <i>Am J Kidney Dis.</i> 2001;38(5):988-991. doi: 10.1053/ajkd.2001.28587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/11684551/pubmed" id="11684551" target="_blank">11684551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21304025">
<a name="21304025"></a>Coppol E, Shelly J, Cheng S, Kaakeh Y, Shepler B. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population. <i>Ann Pharmacother</i>. 2011;45(2):241-247. doi:10.1345/aph.1P466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21304025/pubmed" id="21304025" target="_blank">21304025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21298748">
<a name="21298748"></a>Crary SE, Hall K, and Buchanan GR, "Intravenous Iron Sucrose for Children With Iron Deficiency Failing to Respond to Oral Iron Therapy," <i>Pediatr Blood Cancer</i>, 2011, 56(4):615-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21298748/pubmed" id="21298748" target="_blank">21298748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20051288">
<a name="20051288"></a>Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. <i>Gynecol Oncol.</i> 2010;116(3):522-525. doi: 10.1016/j.ygyno.2009.12.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/20051288/pubmed" id="20051288" target="_blank">20051288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27199624">
<a name="27199624"></a>Danko I. Response of iron deficiency anemia to intravenous iron sucrose in pediatric inflammatory bowel disease. <i>J Pediatr Pharmacol Ther</i>. 2016a;21(2):162-168. doi:10.5863/1551-6776-21.2.162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/27199624/pubmed" id="27199624" target="_blank">27199624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27540710">
<a name="27540710"></a>Danko I, Weidkamp M. Correction of iron deficiency anemia with intravenous iron sucrose in children with inflammatory bowel disease. <i>J Pediatr Gastroenterol Nutr</i>. 2016b;63(5):e107-e111. doi:10.1097/MPG.0000000000001383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/27540710/pubmed" id="27540710" target="_blank">27540710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28189173">
<a name="28189173"></a>DeLoughery TG. Iron deficiency anemia. <i>Med Clin North Am.</i> 2017;101(2):319-332. doi:10.1016/j.mcna.2016.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28189173/pubmed" id="28189173" target="_blank">28189173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18280205">
<a name="18280205"></a>Earley CJ, Horská A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. <i>Sleep Med</i>. 2009;10(2):206-211. doi:10.1016/j.sleep.2007.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/18280205/pubmed" id="18280205" target="_blank">18280205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;(49)(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22877242">
<a name="22877242"></a>Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. <i>Acta Oncol.</i> 2013;52(1):18-29. doi:10.3109/0284186X.2012.702921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/22877242/pubmed" id="22877242" target="_blank">22877242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22435497">
<a name="22435497"></a>Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. <i>Eur J Haematol</i>. 2012;89(1):87-93. doi:10.1111/j.1600-0609.2012.01783.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/22435497/pubmed" id="22435497" target="_blank">22435497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30121943">
<a name="30121943"></a>Govindappagari S, Burwick RM. Treatment of iron deficiency anemia in pregnancy with intravenous versus oral iron: systematic review and meta-analysis. <i>Am J Perinatol</i>. 2019;36(4):366-376. doi:10.1055/s-0038-1668555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30121943/pubmed" id="30121943" target="_blank">30121943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32947565">
<a name="32947565"></a>Goyal A, Zheng Y, Albenberg LG, et al. Anemia in children with inflammatory bowel disease: a position paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2020;71(4):563-582. doi:10.1097/MPG.0000000000002885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/32947565/pubmed" id="32947565" target="_blank">32947565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489063">
<a name="19489063"></a>Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. <i>Mov Disord</i>. 2009;24(10):1445-1452. doi:10.1002/mds.22562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/19489063/pubmed" id="19489063" target="_blank">19489063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31448677">
<a name="31448677"></a>Hamm RF, Blauvelt C, Wang EY, Srinivas SK. Effectiveness of antepartum intravenous iron sucrose: dose timing and impact on outcomes. <i>J Matern Fetal Neonatal Med</i>. 2021;34(12):1983-1990. doi:10.1080/14767058.2019.1656189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31448677/pubmed" id="31448677" target="_blank">31448677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17252006">
<a name="17252006"></a>Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. <i>Leukemia</i>. 2007;21(4):627-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/17252006/pubmed" id="17252006" target="_blank">17252006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31940698">
<a name="31940698"></a>Juul SE, Comstock BA, Wadhawan R, et al. A randomized trial of erythropoietin for neuroprotection in preterm infants. <i>N Engl J Med</i>. 2020;382(3):233-243. doi:10.1056/NEJMoa1907423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31940698/pubmed" id="31940698" target="_blank">31940698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28562517">
<a name="28562517"></a>Kaneva K, Chow E, Rosenfield CG, Kelly MJ. Intravenous iron sucrose for children with iron deficiency anemia. <i>J Pediatr Hematol Oncol</i>. 2017;39(5):e259-e262. doi:10.1097/MPH.0000000000000879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28562517/pubmed" id="28562517" target="_blank">28562517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed June 17, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17234260">
<a name="17234260"></a>Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. <i>Gynecol Oncol.</i> 2007;105(1):199-204. doi:10.1016/j.ygyno.2006.11.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/17234260/pubmed" id="17234260" target="_blank">17234260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31477259">
<a name="31477259"></a>Kshirsagar AV, Li X. Long-term risks of intravenous iron in end-stage renal disease patients. <i>Adv Chronic Kidney Dis</i>. 2019;26(4):292-297. doi:10.1053/j.ackd.2019.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31477259/pubmed" id="31477259" target="_blank">31477259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365964">
<a name="15365964"></a>Leijn E, Monnens LA, and Cornelissen EA, “Intravenous Iron Supplementation in Children on Hemodialysis,” <i>J Nephrol</i>, 2004, 17(3):423-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/15365964/pubmed" id="15365964" target="_blank">15365964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30692612">
<a name="30692612"></a>Lewkowitz AK, Gupta A, Simon L, et al. Intravenous compared with oral iron for the treatment of iron-deficiency anemia in pregnancy: a systematic review and meta-analysis. <i>J Perinatol</i>. 2019;39(4):519-532. doi:10.1038/s41372-019-0320-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30692612/pubmed" id="30692612" target="_blank">30692612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30937914">
<a name="30937914"></a>Lim W, Afif W, Knowles S, et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. <i>Vox Sang</i>. 2019;114(4):363-373. doi:10.1111/vox.12773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30937914/pubmed" id="30937914" target="_blank">30937914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23950195">
<a name="23950195"></a>Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. <i>BMJ</i>. 2013;347:f4822. doi:10.1136/bmj.f4822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/23950195/pubmed" id="23950195" target="_blank">23950195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26759045">
<a name="26759045"></a>Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2016;89(1):28-39. doi:10.1016/j.kint.2015.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26759045/pubmed" id="26759045" target="_blank">26759045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32297281">
<a name="32297281"></a>Macdougall IC, Comin-Colet J, Breymann C, Spahn DR, Koutroubakis IE. Iron sucrose: a wealth of experience in treating iron deficiency. <i>Adv Ther.</i> 2020;37(5):1960-2002. doi:10.1007/s12325-020-01323-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/32297281/pubmed" id="32297281" target="_blank">32297281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955552">
<a name="19955552"></a>MacKay M, Rusho W, Jackson D, et al, "Physical and Chemical Stability of Iron Sucrose in Parenteral Nutrition," <i>Nutr Clin Pract</i>, 2009, 24(6):733-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/19955552/pubmed" id="19955552" target="_blank">19955552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14718064">
<a name="14718064"></a>Manley HJ, Grabe DW. Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitro study. <i>BMC Nephrol</i>. 2004;5:1. doi:10.1186/1471-2369-5-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/14718064/pubmed" id="14718064" target="_blank">14718064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8765624">
<a name="8765624"></a>Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. <i>J Pediatr</i>. 1996;129(2):258-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/8765624/pubmed" id="8765624" target="_blank">8765624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26845108">
<a name="26845108"></a>Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. <i>Cochrane Database Syst Rev</i>. 2016;2:CD009624. doi:10.1002/14651858.CD009624.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26845108/pubmed" id="26845108" target="_blank">26845108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23543624">
<a name="23543624"></a>Mishra A, Dave N, Viradiya K. Fatal anaphylactic reaction to iron sucrose in pregnancy. <i>Indian J Pharmacol</i>. 2013;45(1):93-94. doi:10.4103/0253-7613.106446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/23543624/pubmed" id="23543624" target="_blank">23543624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29103332">
<a name="29103332"></a>Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. <i>Expert Opin Drug Saf</i>. 2018;17(2):149-159. doi:10.1080/14740338.2018.1400009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/29103332/pubmed" id="29103332" target="_blank">29103332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAS.2020">
<a name="NAS.2020"></a>National Academies of Sciences, Engineering, and Medicine 2020. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21586412">
<a name="21586412"></a>Norman JL and Crill CM, "Optimizing the Transition to Home Parenteral Nutrition in Pediatric Patients," <i>Nutr Clin Pract</i>, 2011, 26(3):273-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21586412/pubmed" id="21586412" target="_blank">21586412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28392254">
<a name="28392254"></a>Parrott J, Frank L, Rabena R, et al. American Society for Metabolic and Bariatric Surgery integrated health nutritional guidelines for the surgical weight loss patient 2016 update: micronutrients. <i>Surg Obes Relat Dis</i>. 2017;13(5):727-741.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28392254/pubmed" id="28392254" target="_blank">28392254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21972052">
<a name="21972052"></a>Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. <i>J Cancer Res Clin Oncol.</i> 2012;138(2):179-187. doi:10.1007/s00432-011-1072-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21972052/pubmed" id="21972052" target="_blank">21972052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18605353">
<a name="18605353"></a>Pinsk V, Levy J, Moser A, et al, "Efficacy and Safety of Intravenous Iron Sucrose Therapy in a Group of Children With Iron Deficiency Anemia,"<i> Isr Med Assoc J</i>, 2008, 10(5):335-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/18605353/pubmed" id="18605353" target="_blank">18605353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11134438">
<a name="11134438"></a>Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. <i>Pediatrics</i>. 2001a;107(1):78-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/11134438/pubmed" id="11134438" target="_blank">11134438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pollak.1">
<a name="Pollak.1"></a>Pollak A, Widness JA, Lombard KA. Iron supplementation during erythropoietin treatment. <i>Pediatrics</i>. 2001b;108(6):1390-1391.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28921558">
<a name="28921558"></a>Qassim A, Mol BW, Grivell RM, et al. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review. <i>Aust N Z J Obstet Gynaecol</i>. 2018;58(1):22-39. doi: 10.1111/ajo.12695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28921558/pubmed" id="28921558" target="_blank">28921558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31441077">
<a name="31441077"></a>Qassim A, Grivell RM, Henry A, Kidson-Gerber G, Shand A, Grzeskowiak LE. Intravenous or oral iron for treating iron deficiency anaemia during pregnancy: systematic review and meta-analysis. <i>Med J Aust</i>. 2019;211(8):367-373. doi:10.5694/mja2.50308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31441077/pubmed" id="31441077" target="_blank">31441077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30814805">
<a name="30814805"></a>Radhika AG, Sharma AK, Perumal V, et al. Parenteral versus oral iron for treatment of iron deficiency anaemia during pregnancy and post-partum: a systematic review. <i>J Obstet Gynaecol India</i>. 2019;69(1):13-24. doi:10.1007/s13224-018-1191-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30814805/pubmed" id="30814805" target="_blank">30814805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25420283">
<a name="25420283"></a>Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. <i>Haematologica</i>. 2014;99(11):1671-1676. doi:10.3324/haematol.2014.111492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/25420283/pubmed" id="25420283" target="_blank">25420283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342303">
<a name="26342303"></a>Ribeiro S, Belo L, Reis F, Santos-Silva A. Iron therapy in chronic kidney disease: recent changes, benefits and risks. <i>Blood Rev</i>. 2016;30(1):65-72. doi:10.1016/j.blre.2015.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26342303/pubmed" id="26342303" target="_blank">26342303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34171281">
<a name="34171281"></a>Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. <i>Lancet Haematol</i>. 2021;8(7):e503-e512. doi:10.1016/S2352-3026(21)00137-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/34171281/pubmed" id="34171281" target="_blank">34171281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27091216">
<a name="27091216"></a>Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. <i>Drugs</i>. 2016;76(7):741-757. doi:10.1007/s40265-016-0569-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/27091216/pubmed" id="27091216" target="_blank">27091216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29153377">
<a name="29153377"></a>Rostoker G, Vaziri ND. Iatrogenic iron overload and its potential consequences in patients on hemodialysis. <i>Presse Med</i>. 2017;46(12 pt 2):e312-e328. doi:10.1016/j.lpm.2017.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/29153377/pubmed" id="29153377" target="_blank">29153377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31338466">
<a name="31338466"></a>Rostoker G, Vaziri ND. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. <i>Heliyon</i>. 2019;5(7):e02045. doi:10.1016/j.heliyon.2019.e02045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/31338466/pubmed" id="31338466" target="_blank">31338466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29956370">
<a name="29956370"></a>Rostoker G. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? <i>Semin Dial</i>. 2019;32(1):22-29. doi:10.1111/sdi.12732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/29956370/pubmed" id="29956370" target="_blank">29956370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21355067">
<a name="21355067"></a>Rottembourg J, Kadri A, Leonard E, et al, "Do Two Intravenous Iron Sucrose Preparations Have the Same Efficacy?" <i>Nephrol Dial Transplant</i>, 2011, 26(10):3262-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21355067/pubmed" id="21355067" target="_blank">21355067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16279906">
<a name="16279906"></a>Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. <i>Am J Gastroenterol. </i>2005;100(11):2503-2509. doi:10.1111/j.1572-0241.2005.00250.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/16279906/pubmed" id="16279906" target="_blank">16279906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34767026">
<a name="34767026"></a>Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. <i>JAMA Netw Open</i>. 2021;4(11):e2133935. doi:10.1001/jamanetworkopen.2021.33935<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/34767026/pubmed" id="34767026" target="_blank">34767026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011020">
<a name="34011020"></a>Shin HW, Go DY, Lee SW, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2021;100(20):e24571. doi:10.1097/MD.0000000000024571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/34011020/pubmed" id="34011020" target="_blank">34011020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force Recommendation Statement. <i>Ann Intern Med</i>. 2015;163(7):529-36. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22181342">
<a name="22181342"></a>Stein J, Dignass A, and Chow KU, "Clinical Case Reports Raise Doubts About the Therapeutic Equivalence of an Iron Sucrose Similar Preparation Compared With Iron Sucrose Originator," <i>Curr Med Res Opin</i>, 2012, 28(2):241-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/22181342/pubmed" id="22181342" target="_blank">22181342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28704225">
<a name="28704225"></a>Stein RE, Plantz K, Maxwell EC, Mamula P, Baldassano RN. Intravenous iron sucrose for treatment of iron deficiency anemia in pediatric inflammatory bowel disease. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(2):e51-e55. doi:10.1097/MPG.0000000000001684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/28704225/pubmed" id="28704225" target="_blank">28704225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33248279">
<a name="33248279"></a>Stojanovic S, Graudins LV, Aung AK, Grannell L, Hew M, Zubrinich C. Safety of intravenous iron following infusion reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(4):1660-1666. doi:10.1016/j.jaip.2020.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/33248279/pubmed" id="33248279" target="_blank">33248279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30578747">
<a name="30578747"></a>Sultan P, Bampoe S, Shah R, et al. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;221(1):19.e3-29.e3. doi:10.1016/j.ajog.2018.12.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/30578747/pubmed" id="30578747" target="_blank">30578747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26265306">
<a name="26265306"></a>Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. <i>Br J Pharmacol</i>. 2015;172(21):5025-5036. doi:10.1111/bph.13268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26265306/pubmed" id="26265306" target="_blank">26265306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10873877">
<a name="10873877"></a>Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. <i>Am J Kidney Dis</i>. 2000;36(1):88-97. doi:10.1053/ajkd.2000.8276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/10873877/pubmed" id="10873877" target="_blank">10873877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venofer.1">
<a name="Venofer.1"></a>Venofer (iron sucrose) [prescribing information]. Shirley, NY: American Regent Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venofer.2">
<a name="Venofer.2"></a>Venofer (iron sucrose) [prescribing information]. Shirley, NY: American Regent Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venofer.4">
<a name="Venofer.4"></a>Venofer (iron sucrose) [prescribing information]. Waltham, MA: Fresenius Medical Care NA; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venofer.3">
<a name="Venofer.3"></a>Venofer (iron sucrose) [product monograph]. Richmond Hill, Ontario, Canada: Fresenius Medical Care Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26575062">
<a name="26575062"></a>Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. <i>JAMA</i>. 2015;314(19):2062-2068. doi:10.1001/jama.2015.15572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/26575062/pubmed" id="26575062" target="_blank">26575062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). <i>Guideline: Iron Supplementation in Postpartum Women</i>. World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13058 Version 227.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
